SUMMARY
The numbers of COVID-19 cases in India have surged significantly since mid-May 2025, with daily case counts increasing from sub-few tens to over 300. This rise correlates with elevated viral load in wastewater surveillance, linking to the Omicron variant (BA.1.529), which is known to be the latest circulating variant of concern. JHave identified as JN.1, the dominant variant, has been associated with a "Pirola" sub-variant, and JN.1 is widely recognized as the predominant SARS-CoV-2 variant in India. Recent data suggests that JN.1 is not a new, emerging variant, contradicting previous observations of SARS-CoV-2 variants linked to the Omicron wave in 2022.
The Indian population has "hybrid immunity" to JN.1, meaning individuals have partially immunity from natural infections and have received inadequate doses of胞 novo(novel) vaccines. This has mitigated the risk of severe illness, as most cases are mild. Elevated testing and surveillance counts are attributed to delayed testing protocols, which have led to misleading rises in CRM (case positive rates) and clinical disease prevalence. Despite these challenges, the situation remains under control, with no clinically detected cases or deaths in recent months.
Understanding the role of hybrid immunity in COVID-19 prevention and treatment is critical. Current evidence suggests that COVID-19 resembles other mild respiratory illnesses, emphasizing the need for rational approach to reporting and response. Central governments, along with the public, should focus on reducing anxiety and adopting a balanced strategy to address surges without sentiment-based alarms. Mapping favorable signs from wildlife may be a useful clue for future strategies but should not overshadow addressing current health challenges.